#sglt2-inhibitors #chronic-kidney-disease #empagliflozin #cardiorenal-outcomes #nephroprotection

SGLT2 Inhibitors in Chronic Kidney Disease

Definition

Sodium–glucose cotransporter 2 (SGLT2) inhibitors block renal proximal tubule glucose reabsorption, causing glycosuria. Beyond glycaemic effects, they exert powerful cardiorenal protection in CKD through tubuloglomerular feedback restoration (reduced hyperfiltration), intraglomerular pressure reduction, natriuresis, reduction in tubular oxygen demand, anti-inflammatory and anti-fibrotic effects, and possibly direct cardiac effects. Multiple large RCTs have established them as the first pharmacotherapy class to demonstrate consistent renoprotection in a broad spectrum of CKD — independent of diabetes status, eGFR level, and albuminuria category.

Key Concepts

Mechanism of Renoprotection

Primary haemodynamic mechanism: SGLT2 inhibition reduces glucose and sodium reabsorption in the proximal tubule → increased sodium delivery to the macula densa → tubuloglomerular feedback activation → afferent arteriole constriction → reduced intraglomerular pressure → attenuated hyperfiltration and nephron loss (sources/empagliflozin-empakidney-nejm-2025, rating: very high)
Acute eGFR dip on initiation (early intraglomerular pressure reduction) is haemodynamic and reversible within 4 weeks of stopping — it is NOT nephrotoxic; acute dip is paradoxically associated with improved long-term outcomes (sources/AKI-HF-AHA-2024, rating: very high; sources/empagliflozin-empakidney-nejm-2025, rating: very high)
Non-haemodynamic mechanisms: reduced tubular oxygen demand and ischaemia risk, NLRP3 inflammasome suppression, reduced oxidative stress, cardiomyocyte metabolic shift toward ketone bodies, and direct reduction of cardiac fibrosis (sources/empagliflozin-hfref-nejm-2020, rating: very high)

EMPA-KIDNEY: Active Trial Results

Empagliflozin 10 mg OD vs placebo; n=6,609; eGFR 20–44 (any UACR) or eGFR 45–89 (UACR ≥200); median 2 years; stopped early for efficacy (sources/empagliflozin-empakidney-nejm-2025, rating: very high)
Primary composite (kidney disease progression or CV death): HR 0.72 (95% CI 0.64–0.82) during active trial
Benefits in both diabetic and non-diabetic CKD, across all eGFR strata down to eGFR 20, and across albuminuria categories including low UACR
Kidney disease progression defined as: sustained ≥40% eGFR reduction, ESKD, sustained eGFR <10, or death from kidney failure

EMPA-KIDNEY: Post-Trial Legacy Effect

2-year post-trial observation (no trial drug) in 4,891 consenting survivors (sources/empagliflozin-empakidney-nejm-2025, rating: very high)
Combined active + post-trial primary outcome: HR 0.79 (95% CI 0.72–0.87); ESKD HR 0.74; CV death HR 0.75
Post-trial period alone: primary outcome HR 0.87 (95% CI 0.76–0.99), with attenuating hazard: 6-month HR 0.60, year 1 HR 0.76, year 2 HR 0.90 (NS)
Clinical implication: A ~12-month "legacy effect" exists after stopping empagliflozin, but benefit is not permanent — long-term uninterrupted treatment is necessary to maximise cardiorenal protection
Open-label SGLT2i uptake was ~40–43% in both post-trial groups; the true legacy effect is likely larger than estimated due to this dilution

Spectrum of Patients Who Benefit

Benefit is consistent across diabetic and non-diabetic CKD (sources/empagliflozin-empakidney-nejm-2025, rating: very high)
Benefit extends to low-albuminuria/normoalbuminuric patients in the low-eGFR group — expanding eligibility beyond albuminuric CKD (sources/empagliflozin-empakidney-nejm-2025, rating: very high)
eGFR as low as 20 mL/min/1.73m²: benefit maintained; KDIGO 2024 guidelines recommend SGLT2i in CKD despite low eGFR
No increase in non-cardiovascular death at any eGFR level (HR 0.97 for non-CV death in EMPA-KIDNEY)

SGLT2i in CKD + Heart Failure

In HFrEF with CKD: DAPA-HF and EMPEROR-Reduced showed renal composite HR 0.50–0.68; eGFR decline 4× slower with empagliflozin (sources/empagliflozin-hfref-nejm-2020, rating: very high)
In HFpEF: EMPEROR-Preserved and DELIVER established Class I, Level A for empagliflozin/dapagliflozin; slower eGFR decline in both trials (sources/empagliflozin-hfpef-nejm-2021, rating: very high)
ESC 2023 update: SGLT2i Class I for HFmrEF/HFpEF; finerenone + SGLT2i complementary for CKD + T2DM (sources/HF-update-ESC-2023, rating: very high)
Initial eGFR dip with SGLT2i in HF is NOT a reason to stop the drug — it is paradoxically associated with improved cardiovascular outcomes and reduced major kidney events (sources/AKI-HF-AHA-2024, rating: very high)

eGFR Monitoring and Drug Continuation

Do NOT stop SGLT2i for eGFR decline alone unless eGFR drops below the pre-specified threshold (generally <20 mL/min/1.73m² or ESKD) (sources/AKI-HF-AHA-2024, rating: very high)
Paradox of GDMT: acute pharmacological eGFR reduction with SGLT2i or RAAS inhibitors reflects haemodynamic tubuloglomerular feedback, not nephron loss (sources/AKI-HF-AHA-2024, rating: very high)
Perioperative management: SGLT2i COR 1 to stop before non-cardiac surgery due to euglycaemic DKA risk (sources/periop-aha-2024, rating: very high)

Contradictions / Open Questions

Mechanism of post-trial legacy effect unclear: Nephron preservation and reduced hyperfiltration are the leading hypotheses, but the persistent ESKD reduction after stopping cannot be fully explained by eGFR reversal alone — direct structural renoprotection is implied but not proven (sources/empagliflozin-empakidney-nejm-2025, rating: very high)
SGLT2i guideline discordance by albuminuria level: Current international guidelines (KDIGO 2024) give different recommendation strengths depending on albuminuria category. EMPA-KIDNEY data show benefit across all albuminuria subgroups including low UACR in low-eGFR patients — guideline update may be warranted (sources/empagliflozin-empakidney-nejm-2025, rating: very high)
Optimal duration unknown: The 12-month legacy effect supports long-term treatment, but no data exist on optimal restart timing if a patient temporarily stops, or whether effects are truly irreversible with sufficiently long treatment duration (sources/empagliflozin-empakidney-nejm-2025, rating: very high)
Evidence gap in very advanced CKD (eGFR <20): EMPA-KIDNEY lower bound was eGFR 20; safety and efficacy below this threshold not established; most patients progressing to ESKD are effectively undertreated pending regulatory label updates
Benefit is context-dependent — SGLT2i do NOT prevent de novo HF post-MI: EMPACT-MI (NEJM 2024; n=6,522) showed empagliflozin started within 14 days of acute MI (LVEF <45% or congestion) did NOT reduce the primary composite of HF hospitalisation or all-cause death (HR 0.90; P=0.21). In contrast, EMPEROR-Reduced (HR 0.75) and DAPA-HF (HR 0.74) showed clear benefit in established HFrEF. The divergence reflects that SGLT2i benefit requires an established chronic substrate (persistent HF, CKD); acute post-MI — with reversible stunning, non-modifiable early deaths, and predominantly STEMI with successful revascularisation — lies outside the current benefit zone. HF hospitalisation alone trended in favour of empagliflozin (HR 0.77), and total HF hospitalisations were markedly reduced (rate ratio 0.67). (sources/empagliflozin-empactmi-nejm-2024, rating: very high)

Connections

Related to concepts/Cardiorenal-Syndrome — CRS Type 4 (uremic cardiomyopathy / chronic renocardiac syndrome)
Related to entities/Heart-Failure — SGLT2i spans HFrEF, HFmrEF, HFpEF and CKD as Class I therapy
Related to entities/HFrEF — EMPEROR-Reduced eGFR and renal composite data
Related to entities/HFpEF — EMPEROR-Preserved and DELIVER renal benefits
Related to entities/Hypertension — CKD and hypertension are co-morbidities; SGLT2i lowers BP ~2–3 mmHg
Related to concepts/Diuretic-Resistance — SGLT2i natriuresis may augment loop diuretic response
Related to entities/Acute-Coronary-Syndrome — EMPACT-MI defines the post-MI boundary of SGLT2i benefit